Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202607017 A Randomized, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety, Tolerability, and Pharmacokinetics of SER-252 in Patients with Parkinson's Disease and Motor Fluctuations New Drug Phase Ⅰ
N202607018 A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD) New Drug Phase Ⅲ
N202607022 An Open-Label, Randomized, and Crossover Bioequivalence Study of Vildagliptin/Metformin Hydrochloride 50/500 mg Film-Coated Tablet in Healthy Subjects under Fed Conditions Bioavailability / Bioequivalence (BA/BE) NA
N202607025 A preliminary bioequivalence study to compare two lurasidone HCl tablets in healthy subjects under fed state. Bioavailability / Bioequivalence (BA/BE) NA
N202607026 An Observational Registry Study to Evaluate the Use and Safety of LEQEMBI in Routine Clinical Practice in Taiwan New Drug PMS(Post Marketing Surveillance)
N202607051 An Exploratory Phase 2 Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Investigate the Safety, Tolerability, and Efficacy of TML-6 in Early Alzheimer’s Disease New Drug Phase Ⅱ
N202607055 AI-Assisted Diagnosis of Liver Tumors New Medical Device NA
N202607060 A phase 3, randomized, parallel, multicenter, double-blind, placebo-controlled study to investigate efficacy and safety of KP-001 in patients aged ≥2 years with common venous malformations, common lymphatic malformations, or KTS/CLOVES syndrome New Drug Phase Ⅲ
N202607069 A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST) New Drug Phase Ⅲ
N202607070 A Phase 1 Clinical Trial of ACE723, A Dual-Payload Antibody Drug Conjugate Targeting Glypican-3 (GPC-3), in Patients with Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Who Have Failed or Progressed on Standard Immune Checkpoint Inhibitor-Containing Systemic Therapies New Drug Phase Ⅰ
1 2 23 24 25 26 27 28 29 30 31 32 / 32

TOP